Teleflex (NYSE:TFX – Get Free Report) was upgraded by stock analysts at Bank of America from a “neutral” rating to a “buy” rating in a report released on Monday, MarketBeat reports. The firm presently has a $158.00 price target on the medical technology company’s stock, up from their prior price target of $145.00. Bank of America‘s price objective would indicate a potential upside of 25.43% from the stock’s previous close.
TFX has been the subject of a number of other reports. UBS Group increased their price objective on shares of Teleflex from $145.00 to $158.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 11th. Zacks Research raised Teleflex from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 24th. Piper Sandler reiterated an “overweight” rating and set a $169.00 target price (up from $160.00) on shares of Teleflex in a report on Friday, August 7th. Weiss Ratings reissued a “sell (d)” rating on shares of Teleflex in a research report on Monday, September 21st. Finally, Needham & Company LLC raised their price target on Teleflex from $159.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, August 25th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Teleflex currently has an average rating of “Moderate Buy” and an average price target of $155.20.
Check Out Our Latest Stock Report on Teleflex
Teleflex Trading Down 1.1%
Teleflex (NYSE:TFX – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical technology company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.48. Teleflex had a negative net margin of 39.67% and a positive return on equity of 11.93%. The company had revenue of $570.33 million during the quarter, compared to analysts’ expectations of $559.59 million. During the same period last year, the business earned $3.73 EPS. The business’s quarterly revenue was up 28.9% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. As a group, analysts anticipate that Teleflex will post 7.26 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. Hsbc Holdings PLC increased its position in Teleflex by 4.7% during the 1st quarter. Hsbc Holdings PLC now owns 1,861 shares of the medical technology company’s stock valued at $222,000 after buying an additional 84 shares in the last quarter. Hantz Financial Services Inc. boosted its holdings in Teleflex by 40.5% in the fourth quarter. Hantz Financial Services Inc. now owns 392 shares of the medical technology company’s stock worth $48,000 after acquiring an additional 113 shares in the last quarter. Leonteq Securities AG boosted its holdings in Teleflex by 13.6% in the first quarter. Leonteq Securities AG now owns 1,164 shares of the medical technology company’s stock worth $139,000 after acquiring an additional 139 shares in the last quarter. CIBC Asset Management Inc grew its stake in shares of Teleflex by 3.4% in the fourth quarter. CIBC Asset Management Inc now owns 4,380 shares of the medical technology company’s stock worth $535,000 after acquiring an additional 145 shares during the last quarter. Finally, Sage Rhino Capital LLC grew its stake in shares of Teleflex by 9.5% in the first quarter. Sage Rhino Capital LLC now owns 1,837 shares of the medical technology company’s stock worth $220,000 after acquiring an additional 159 shares during the last quarter. 95.62% of the stock is owned by institutional investors and hedge funds.
Teleflex News Summary
Here are the key news stories impacting Teleflex this week:
- Positive Sentiment: Bank of America upgraded Teleflex to Buy from Neutral and raised its price target to $158 from $145. The firm cited stronger growth prospects, new leadership and the potential for a 2027 re-rating as the key remaining medical-technology businesses become more focused. BofA Upgrades Teleflex to Buy From Neutral
- Positive Sentiment: Teleflex reported peer-reviewed data showing its Arrowg+ard™ catheter technology was associated with a 70% lower hazard of central line-associated bloodstream infections. The findings could support adoption of the company’s catheter products and strengthen its competitive position in infection prevention. Teleflex Arrowg+ard Study
- Positive Sentiment: The completed $1.5 billion OEM business sale improves financial flexibility. Management plans to use proceeds for approximately $800 million of debt reduction and to complete a $1 billion share-repurchase authorization, which could reduce leverage and support per-share earnings.
- Neutral Sentiment: Analysts and market coverage continue to frame 2026 as a transition year, with improved earnings power expected in 2027. Teleflex’s latest quarterly results exceeded estimates, but reported earnings were well below the prior year, leaving investors focused on execution and the pace of recovery.
- Negative Sentiment: The stock’s recent rally may have prompted profit-taking, while uncertainty around leadership changes, debt management and the timing of post-divestiture growth can limit near-term upside. Teleflex also maintains full-year 2026 adjusted EPS guidance of $6.90–$7.20, below some analysts’ consensus expectations.
About Teleflex
Teleflex Incorporated is a global medical technology company that develops, manufactures and supplies specialty medical devices for hospitals, clinicians and other health care providers. Its products are designed to support procedures in areas including vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgery and urology.
The company’s portfolio includes Arrow branded vascular access and catheter products, airway management devices, regional anesthesia products, surgical instruments, interventional devices and urological products.
Further Reading
- Five stocks we like better than Teleflex
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
- Bottlenecking the Future: TSMC Prices Out the Competition
- Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.
